vs

Side-by-side financial comparison of Bioventus Inc. (BVS) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.

Wheels Up Experience Inc. is the larger business by last-quarter revenue ($183.8M vs $157.9M, roughly 1.2× Bioventus Inc.). Bioventus Inc. runs the higher net margin — 9.3% vs -15.7%, a 25.1% gap on every dollar of revenue. On growth, Bioventus Inc. posted the faster year-over-year revenue change (2.8% vs -10.2%). Bioventus Inc. produced more free cash flow last quarter ($37.4M vs $-58.3M). Over the past eight quarters, Bioventus Inc.'s revenue compounded faster (10.4% CAGR vs -3.4%).

Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.

Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.

BVS vs UP — Head-to-Head

Bigger by revenue
UP
UP
1.2× larger
UP
$183.8M
$157.9M
BVS
Growing faster (revenue YoY)
BVS
BVS
+13.0% gap
BVS
2.8%
-10.2%
UP
Higher net margin
BVS
BVS
25.1% more per $
BVS
9.3%
-15.7%
UP
More free cash flow
BVS
BVS
$95.6M more FCF
BVS
$37.4M
$-58.3M
UP
Faster 2-yr revenue CAGR
BVS
BVS
Annualised
BVS
10.4%
-3.4%
UP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BVS
BVS
UP
UP
Revenue
$157.9M
$183.8M
Net Profit
$14.8M
$-28.9M
Gross Margin
68.9%
14.3%
Operating Margin
12.3%
-0.9%
Net Margin
9.3%
-15.7%
Revenue YoY
2.8%
-10.2%
Net Profit YoY
3902.8%
67.0%
EPS (diluted)
$0.21
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVS
BVS
UP
UP
Q4 25
$157.9M
$183.8M
Q3 25
$138.7M
$185.5M
Q2 25
$147.7M
$189.6M
Q1 25
$123.9M
$177.5M
Q4 24
$153.6M
$204.8M
Q3 24
$139.0M
$193.9M
Q2 24
$151.2M
$196.3M
Q1 24
$129.5M
$197.1M
Net Profit
BVS
BVS
UP
UP
Q4 25
$14.8M
$-28.9M
Q3 25
$3.2M
$-83.7M
Q2 25
$7.5M
$-82.3M
Q1 25
$-2.6M
$-99.3M
Q4 24
$-388.0K
$-87.5M
Q3 24
$-5.2M
$-57.7M
Q2 24
$-25.7M
$-97.0M
Q1 24
$-4.9M
$-97.4M
Gross Margin
BVS
BVS
UP
UP
Q4 25
68.9%
14.3%
Q3 25
68.0%
6.8%
Q2 25
69.1%
8.3%
Q1 25
67.0%
10.8%
Q4 24
66.8%
13.9%
Q3 24
67.3%
13.9%
Q2 24
68.5%
2.3%
Q1 24
68.3%
-0.6%
Operating Margin
BVS
BVS
UP
UP
Q4 25
12.3%
-0.9%
Q3 25
8.1%
-33.1%
Q2 25
12.4%
-31.4%
Q1 25
3.9%
-45.5%
Q4 24
5.0%
-26.0%
Q3 24
2.6%
-21.6%
Q2 24
-20.8%
-40.3%
Q1 24
3.8%
-42.9%
Net Margin
BVS
BVS
UP
UP
Q4 25
9.3%
-15.7%
Q3 25
2.3%
-45.1%
Q2 25
5.1%
-43.4%
Q1 25
-2.1%
-55.9%
Q4 24
-0.3%
-42.7%
Q3 24
-3.7%
-29.8%
Q2 24
-17.0%
-49.4%
Q1 24
-3.8%
-49.4%
EPS (diluted)
BVS
BVS
UP
UP
Q4 25
$0.21
$-0.04
Q3 25
$0.05
$-0.12
Q2 25
$0.11
$-0.12
Q1 25
$-0.04
$-0.14
Q4 24
$0.00
$-0.13
Q3 24
$-0.08
$-0.08
Q2 24
$-0.40
$-0.14
Q1 24
$-0.08
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVS
BVS
UP
UP
Cash + ST InvestmentsLiquidity on hand
$51.2M
$133.9M
Total DebtLower is stronger
$671.3M
Stockholders' EquityBook value
$184.1M
$-392.1M
Total Assets
$683.6M
$968.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVS
BVS
UP
UP
Q4 25
$51.2M
$133.9M
Q3 25
$42.2M
$125.3M
Q2 25
$32.9M
$107.0M
Q1 25
$22.8M
$171.8M
Q4 24
$41.6M
$216.4M
Q3 24
$43.1M
$115.9M
Q2 24
$32.0M
$141.5M
Q1 24
$25.2M
$180.9M
Total Debt
BVS
BVS
UP
UP
Q4 25
$671.3M
Q3 25
$766.5M
Q2 25
$770.5M
Q1 25
$765.8M
Q4 24
$761.3M
Q3 24
$596.9M
Q2 24
$597.4M
Q1 24
$603.2M
Stockholders' Equity
BVS
BVS
UP
UP
Q4 25
$184.1M
$-392.1M
Q3 25
$166.1M
$-374.5M
Q2 25
$161.2M
$-347.8M
Q1 25
$148.1M
$-288.1M
Q4 24
$147.9M
$-202.1M
Q3 24
$148.7M
$-117.7M
Q2 24
$150.9M
$-72.2M
Q1 24
$171.3M
$936.0K
Total Assets
BVS
BVS
UP
UP
Q4 25
$683.6M
$968.8M
Q3 25
$701.6M
$973.0M
Q2 25
$706.8M
$1.0B
Q1 25
$691.4M
$1.1B
Q4 24
$728.0M
$1.2B
Q3 24
$769.5M
$1.0B
Q2 24
$792.2M
$1.1B
Q1 24
$794.2M
$1.2B
Debt / Equity
BVS
BVS
UP
UP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
644.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVS
BVS
UP
UP
Operating Cash FlowLast quarter
$38.0M
$-18.4M
Free Cash FlowOCF − Capex
$37.4M
$-58.3M
FCF MarginFCF / Revenue
23.7%
-31.7%
Capex IntensityCapex / Revenue
0.4%
21.7%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$72.1M
$-259.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVS
BVS
UP
UP
Q4 25
$38.0M
$-18.4M
Q3 25
$30.1M
$-37.1M
Q2 25
$25.9M
$-62.9M
Q1 25
$-19.3M
$-47.9M
Q4 24
$19.3M
$37.9M
Q3 24
$10.3M
$-16.9M
Q2 24
$15.2M
$-25.2M
Q1 24
$-6.0M
$-73.8M
Free Cash Flow
BVS
BVS
UP
UP
Q4 25
$37.4M
$-58.3M
Q3 25
$29.6M
$-60.4M
Q2 25
$25.3M
$-78.6M
Q1 25
$-20.2M
$-62.6M
Q4 24
$18.7M
$-70.2M
Q3 24
$10.3M
$-21.9M
Q2 24
$15.1M
$-30.8M
Q1 24
$-6.3M
$-77.8M
FCF Margin
BVS
BVS
UP
UP
Q4 25
23.7%
-31.7%
Q3 25
21.4%
-32.6%
Q2 25
17.1%
-41.5%
Q1 25
-16.3%
-35.3%
Q4 24
12.2%
-34.3%
Q3 24
7.4%
-11.3%
Q2 24
10.0%
-15.7%
Q1 24
-4.9%
-39.5%
Capex Intensity
BVS
BVS
UP
UP
Q4 25
0.4%
21.7%
Q3 25
0.3%
12.5%
Q2 25
0.5%
8.3%
Q1 25
0.7%
8.3%
Q4 24
0.4%
52.8%
Q3 24
0.0%
2.6%
Q2 24
0.1%
2.9%
Q1 24
0.2%
2.0%
Cash Conversion
BVS
BVS
UP
UP
Q4 25
2.57×
Q3 25
9.54×
Q2 25
3.48×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BVS
BVS

Pain Treatments$71.1M45%
Surgical Solutions$48.9M31%
Restorative Therapies$19.5M12%
Other$18.4M12%

UP
UP

Segment breakdown not available.

Related Comparisons